Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ZD1839 ('Iressa') as an anticancer agent.

J Baselga1, S D Averbuch

  • 1Medical Oncology Service, Vail d'Hebron University Hospital, Barcelona, Spain.

Drugs
|December 29, 2000
PubMed
Summary

ZD1839 (Iressa) is a targeted therapy blocking cancer cell growth. Early trials show it is well-tolerated and effective, especially for non-small cell lung cancer (NSCLC).

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESMO's new strategic plan: our society's road to the future of oncology.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Annals of oncology : official journal of the European Society for Medical Oncology·2019

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Epidermal growth factor receptor (EGFR) signaling pathways are crucial for cancer cell proliferation and survival.
  • Targeting EGFR-tyrosine kinase offers a potential strategy for cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of ZD1839 (Iressa), a selective EGFR-tyrosine kinase inhibitor.
  • To explore the potential of ZD1839 in various cancer types, with a focus on non-small cell lung cancer (NSCLC).

Main Methods:

  • Preclinical studies involving tumor cell lines and xenografts.
  • Phase I clinical trials in patients with advanced cancers.
  • Assessment of ZD1839's impact on tumor growth and patient tolerability.

Main Results:

  • ZD1839 demonstrated reversible tumor growth inhibition and delay in preclinical models.
  • Co-administration with cytotoxic agents enhanced ZD1839's anti-tumor activity.
  • Phase I trials indicated an acceptable safety profile and promising clinical efficacy, particularly in NSCLC patients.

Conclusions:

  • ZD1839 is a promising targeted therapy for cancer treatment.
  • Its efficacy is notable in non-small cell lung cancer (NSCLC).
  • Further clinical development, including Phase III trials for NSCLC, is warranted.

Related Experiment Videos